{"prompt": "['Novartis', 'Confidential', 'Page 64', 'Amended Protocol Version 03 (Clean)', 'Protocol No. CQAW039A2322', '15', 'References', 'References are available upon request', 'Bachert C, Mannent L, Naclerio RM, et al (2016) Effect of Subcutaneous Dupilumab on', 'Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized', 'Clinical Trial. JAMA p. 469-79.', 'Bretz F, Posch M, Glimm E, et al (2011) Graphical approaches for multiple comparison', 'procedures using weighted Bonferroni, Simes, or parametric tests. Biom J p. 894-913.', 'Castro M, Mathur S, Hargreave F, et al (2011) Reslizumab for poorly controlled, eosinophilic', 'asthma: a randomized, placebo-controlled study. Am. J. Respir. Crit. Care Med. p. 1125-32.', 'Castro M, Zangrilli J, Wechsler ME, et al (2015) Reslizumab for inadequately controlled', 'asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-', 'blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med p. 355-66.', 'Chevalier E, Stock J, Fisher T, et al (2005) Cutting edge: chemoattractant receptor-', 'homologous molecule expressed on Th2 cells plays a restricting role on IL-5 production and', 'eosinophil recruitment. J. Immunol. p. 2056-60.', 'Deng JW, Song IS, Shin HJ, et al (2008) The effect of SLCO1B1* 15 on the disposition of', 'pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity', 'changes by SLCO1B1* 15. Pharmacogenet. Genomics p. 424-33.', 'Elsby R, Hilgendorf C, Fenner K (2012) Understanding the critical disposition pathways of', \"statins to assess drug-drug interaction risk during drug development: it's not just about\", 'OATP1B1. Clin. Pharmacol. Ther. p. 584-98.', 'Gevaert P, Calus L, Van Zele T, et al (2013) Omalizumab is effective in allergic and', 'nonallergic patients with nasal polyps and asthma. J. Allergy Clin. Immunol. p. 110-6.e1.', 'Jacobson TA (2008) Toward \"pain-free\" statin prescribing: clinical algorithm for diagnosis', 'and management of myalgia. Mayo Clin. Proc. p. 687-700.', \"Juniper EF, O'Byrne PM, Guyatt GH, et al. 1999. Development and validation of a\", 'questionnaire to measure asthma control. Eur. Respir. J.. 14(4):902-7.', 'Juniper EF, Svensson K, M\u00f6rk AC, et al (2005) Measurement properties and interpretation of', 'three shortened versions of the asthma control questionnaire. Respir Med p. 553-8.', 'Kalliokoski A, Niemi M (2009) Impact of OATP transporters on pharmacokinetics. Br. J.', 'Pharmacol. p. 693-705.', 'Larsen K The clinical relationship of nasal polyps to asthma. Allergy Asthma Proc p. 243-9.', 'Mj\u00f6sberg JM, Trifari S, Crellin NK, et al (2011) Human IL-25- and IL-33-responsive type 2', 'innate lymphoid cells are defined by expression of CRTH2 and CD161. Nat. Immunol. p.', '1055-62.', 'Newton JR, Ah-See KW (2008) A review of nasal polyposis. Ther Clin Risk Manag p. 507-', '12.']['Novartis', 'Confidential', 'Page 65', 'Amended Protocol Version 03 (Clean)', 'Protocol No. CQAW039A2322', 'No\u00e9 J, Portmann R, Brun ME, et al (2007) Substrate-dependent drug-drug interactions', 'between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP)', 'substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab. Dispos. p. 1308-14.', 'Orlandi RR, Kingdom TT, Hwang PH, et al (2016) International Consensus Statement on', 'Allergy and Rhinology: Rhinosinusitis. Int Forum Allergy Rhinol p. S22-209.', 'Pavord ID, Korn S, Howarth P, et al (2012) Mepolizumab for severe eosinophilic asthma', '(DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet p. 651-9.', 'P\u00e9rez-Novo CA, Holtappels G, Vinall SL, et al (2010) CRTH2 mediates the activation of', 'human Th2 cells in response to PGD(2) released from IgE/anti-IgE treated nasal polyp tissue.', 'Allergy p. 304-10.', 'Regan SL, Maggs JL, Hammond TG, et al (2010) Acyl glucuronides: the good, the bad and', 'the ugly. Biopharm Drug Dispos p. 367-95.', 'Shaw JL, Ashoori F, Fakhri S, et al Increased percentage of mast cells within sinonasal', 'mucosa of chronic rhinosinusitis with nasal polyp patients independent of atopy. Int Forum', 'Allergy Rhinol p. 233-40.', 'Yamamoto M, Okano M, Fujiwara T, et al (2009) Expression and characterization of PGD2', 'receptors in chronic rhinosinusitis: modulation of DP and CRTH2 by PGD2. Int. Arch.', 'Allergy Immunol. p. 127-36.']\n\n###\n\n", "completion": "END"}